Galina V. Shchelkova

Galina V. Shchelkova

Auto-generated profile, based on publicly available information

Galina V. Shchelkova

Chazov National Medical Research Center of Cardiology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AAAnna V. Aksenova
Anna V. Aksenova
OSOlga A. Sivakova
Olga A. Sivakova
NBNataliia V. Blinova
Nataliia V. Blinova
NDNikolai M. Danilov
Nikolai M. Danilov
EEEvgeniia M. Elfimova
Evgeniia M. Elfimova
ICIrina E. Chazova
Irina E. Chazova
The diagnosis of resistant arterial hypertension allows us to single out a separate group of patients in whom it is necessary to use special diagnostic methods and approaches to treatment. Elimination of reversible factors leading to the development of resistant arterial hypertension, such as non-adherence to therapy, inappropriate therapy, secondary forms of arterial hypertension, leads to an improvement in the patient's prognosis. Most patients with resistant hypertension should be evaluated to rule out primary aldosteronism, renal artery stenosis, chronic kidney disease, and obstructive sleep apnea. The algorithm for examining patients, recommendations for lifestyle changes and a step-by-step therapy plan can improve blood pressure control. It is optative to use the most simplified treatment regimen and long-acting combined drugs. For a separate category of patients, it is advisable to perform radiofrequency denervation of the renal arteries.

25 December 2024 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
ICI. E. Chazova
I. E. Chazova
NCN. M. Chikhladze
N. M. Chikhladze
NBN. V. Blinova
N. V. Blinova
AAA. V. Aksenova
A. V. Aksenova
TAT. A. Alekseeva
T. A. Alekseeva
GSG. V. Shchelkova
G. V. Shchelkova
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.

26 June 2023 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
GSG. V. Shchelkova
G. V. Shchelkova
NDN. M. Danilov
N. M. Danilov
AEA. M. Erkenova
A. M. Erkenova
SYS. Yu. Yarovoy
S. Yu. Yarovoy
YMYu. G. Matchin
Yu. G. Matchin
МШМ. Ю. Швецов
М. Ю. Швецов
The clinical significance of renovascular arterial hypertension is determined by it is high prevalence as well as it is negative impact on prognosis. The most common causes of renovascular arterial hypertension are atherosclerotic stenosis of the renal arteries and fibromuscular dysplasia. Renovascular arterial hypertension is characterized by the development of blood pressure resistant to antihypertensive therapy with an unfavorable prognosis of worsening renal function and cardiovascular complications. Currently, the most available screening method in the diagnosis of renovascular arterial hypertension is duplex scanning of the renal arteries. Non-invasive diagnostic methods also include magnetic resonance and multispiral computed tomography with intravenous contrast. Contrast angiography remains “the golden standard” for diagnosing renovascular arterial hypertension and determining the indications for surgical treatment. Together with the use of diagnostic techniques such as measurement of translesion pressure gradient and fractional blood flow reserve, it allows to assess the functional significance of renal artery stenosis. Treatment of renovascular arterial hypertension is a complex process aimed at normalization of blood pressure, improvement of renal function, as well as mortality and cardiovascular risk reduction. To date, the feasibility of endovascular treatment remains an open question. More often the preference is given to conservative treatment. The indications for renal artery revascularization are less obvious, available clinical guidelines and results of large trials are controversial.

1 September 2016 in Journal Of Hypertension
Verified
Journal Article
Closed access
GSG. Shchelkova
G. Shchelkova
AZA. Zairova
A. Zairova
NDN. Danilov
N. Danilov
ARA. Rogoza
A. Rogoza
ICI. Chazova
I. Chazova
Objective: We study the effect of renal denervation (RDN) on arterial stiffness and arterial functional in patients with resistant hypertension 6 months after RDN. Design and method: We examined 21 patients, average 57 ± 10 years, before and 6 months after successful RDN. Initially mean blood pressure was 174 ± 12 mmHg. All patients continued take the original multicomponent antihypertensive therapy unchanged. Arterial stiffness was determined by volume sphygmograph (VaSera 1000) we assessed pulse wave velocity aortic (PWA) and cardio-ankle vascular index (CAVI); by applanation tonometry (SPhygmoCor) - carotid-femoral pulse wave velocity (PWVcf); by ultrasound method echo-TRACKING technology (Aloka Prosound α7) - stiffness index (B), modulus of elastic deformation (Ep), artery distensibility (AC). Endothelial function was evaluated by finger photoplethysmography during reactive hyperemia (Angioscan-01). We assessed the occlusion amplitude index for the determination of endothelial function in the microvasculature and the occlusion phase shift index for the determination of endothelial function in the arteries of muscular type. Six months after RDN 12 patients were classified as responders (mean systolic BP was reduced on 10 mmHg and more). Results: At baseline arterial stiffness was increased in 19 patients (90%) by PWVcf, in 13 (62%) by CAVI, PWA – 8 (38%), index B – 4 (19%), EP – 10 (48%), AC – 5 (24%). Baseline endothelial dysfunction was found in 17 patients (81%) by occlusion amplitude index, in 18 (85%) by occlusion phase shift index. 6 months after RDN in responders PWVcf decreased from 13,7 ± 3,6 to 12,5 ± 3,1 m/s (p < 0,01), CAVI from 7,08 ± 3,4 to 6,02 ± 3,8 (p < 0,05), AC increased from 0,71 ± 0,32 to 0,93 ± 0,5 mm2/Kpa (p < 0,05). Endothelial dysfunction had tendency to positive change: occlusion phase shift index increased from 1,28 ± 0,67 to 1,42 ± 0,32 (p = 0,07). All parameters of arterial stiffness and endothelial function had not positive changes in nonresponders. Conclusions: After 6 months of RDN we detected the improvement of some indicators of arterial stiffness and tendency to improve endothelial function in responders.

25 March 2024 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
GSG. V. Schelkova
G. V. Schelkova
SYS. Yu. Yarovoy
S. Yu. Yarovoy
EDE. O. Dinevich
E. O. Dinevich
ICI. E. Chazova
I. E. Chazova
СЯС. Ю. Яровой
С. Ю. Яровой
This review presents current data regarding the relationship between hyperuricemia, obesity, diabetes mellitus, lipid disorders and pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH). Hyperuricemia is associated with a higher risk of developing of PAH, worse prognosis of PAH and greater severity of the patient's condition. Obesity leads to the development of pro-inflammatory and vasoconstrictor effects, hypoxia, which contributes to the progression of PH, however, the survival rate of patients with PH and overweight or obesity is higher than with normal or reduced body weight. Diabetes mellitus and concomitant insulin resistance are associated with a high risk of hospitalization for right ventricular heart failure and mortality. The presence of PAH is associated with lower values of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and probably high-density lipoprotein cholesterol (HDL-C). At the same time, higher levels of LDL-С and HDL-С in PAH and CTEPH determine a better prognosis of the disease.All metabolic disorders considered have common mechanisms of influence on PH. Further study of their pathogenetic basis will make it possible to develop unified approaches to methods of their correction in patients with various types of pulmonary hypertension.

30 December 2025 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
PDF file
SYS.YU. Yarovoy
S.YU. Yarovoy
GSG.V. Shchelkova
G.V. Shchelkova
EDE.O. Dinevich
E.O. Dinevich
ICI.E. Chazova
I.E. Chazova
SBS.A. Boitsov
S.A. Boitsov
Objective. To study the possibility of assessing the adherence to therapy in patients with resistant hypertension (RH) according to Russian-language literature. Material and methods. RH was defined according to clinical guidelines of the Russian Medical Society on Arterial Hypertension (2021). Data were searched in electronic databases and searching engines Google Scholar, eLIBRARY.RU, Central Scientific Medical Library (database inception to 01.12.2023). According to inclusion and exclusion criteria, two independent researchers extracted the articles. Disagreements between researchers were resolved by the third researcher. Study quality was assessed using the Newcastle-Ottawa scale. Results. Among 1610 primary identified publications, 1473 studies were screened. Finally, the authors assessed 49 full-text articles for eligibility. Four studies were selected for qualitative analysis. There were 256 patients. Adherence was assessed using the Morisky—Green questionnaire in original or modified versions. Analysis revealed significant heterogeneity in results. Discussion. Objective assessment of adherence to treatment in this disease and development of measures for its improvement are associated with certain difficulties that limits the number of available studies. The authors performed a systematic review and assessed the possibility of structuring and analyzing the information presented in modern Russian-language literature. Conclusion. Most results indicate low adherence among patients that suggests lower real prevalence of RH, as well as reduced effectiveness of treatment due to non-compliance with drug regimen.